Evidence map›Paper›PMID 41234883›Full record

ArticleTranslational cancer research2025

Anti-ovarian cancer effects of forsythiaside A: insights from

Haocheng Guan, Yongchao Li, Menglong Xu, Wenqiang Sun, Ruijun Shi, Shuwei Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haocheng Guan *Department of Biochemistry and Molecular Biology, College of Life Science and Technology, the State Key Laboratory Incubation Base for Conservation and Utilization of Bio-Resource in the Tarim Basin of the Xinjiang Production and Construction Corps, Tarim University, Alar, China.ORCID https://orcid.org/0009-0006-5245-1534
Yongchao Li *Department of Biochemistry and Molecular Biology, College of Life Science and Technology, the State Key Laboratory Incubation Base for Conservation and Utilization of Bio-Resource in the Tarim Basin of the Xinjiang Production and Construction Corps, Tarim University, Alar, China.
Menglong XuDepartment of Biochemistry and Molecular Biology, College of Life Science and Technology, the State Key Laboratory Incubation Base for Conservation and Utilization of Bio-Resource in the Tarim Basin of the Xinjiang Production and Construction Corps, Tarim University, Alar, China.
Wenqiang SunDepartment of Biochemistry and Molecular Biology, College of Life Science and Technology, the State Key Laboratory Incubation Base for Conservation and Utilization of Bio-Resource in the Tarim Basin of the Xinjiang Production and Construction Corps, Tarim University, Alar, China.
Ruijun ShiDepartment of Biochemistry and Molecular Biology, College of Life Science and Technology, the State Key Laboratory Incubation Base for Conservation and Utilization of Bio-Resource in the Tarim Basin of the Xinjiang Production and Construction Corps, Tarim University, Alar, China.
Shuwei LiDepartment of Biochemistry and Molecular Biology, College of Life Science and Technology, the State Key Laboratory Incubation Base for Conservation and Utilization of Bio-Resource in the Tarim Basin of the Xinjiang Production and Construction Corps, Tarim University, Alar, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ovarian cancer is a significant challenge due to its late-stage diagnosis and high mortality rates. The identification of new therapeutic agents is crucial. Forsythiaside A (FSA), derived from Methods: SK-OV-3 and OVCAR3 ovarian cancer cell lines were used for Results: FSA significantly reduced the proliferation of both SK-OV-3 and OVCAR3 cells in a dose- and time-dependent manner. FSA induced G1 phase cell cycle arrest in both cell lines and inhibited their migration and invasion. It promoted cell death through increased apoptosis and necrosis, with Western blot showing upregulation of pro-apoptotic proteins and downregulation of anti-apoptotic proteins. Transcriptomic analysis revealed significant changes in gene expression, affecting pathways related to cell cycle control, apoptosis, and cancer progression. Conclusions: FSA effectively inhibits ovarian cancer cell proliferation, migration, and invasion, and induces G1 arrest and apoptosis. These results highlight FSA as a promising natural compound for the development of new ovarian cancer treatments.

Indexed as

cell deathforsythiaside A (FSA)invasionmigrationOvarian cancer

Identifiers

PMID41234883
PMCPMC12605461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.